Metyrapone Versus Osilodrostat in the Short-Term Therapy of Endogenous Cushing’s Syndrome: Results From a Single Center Cohort Study

BACKGROUND: Although surgery is considered the first-line treatment for patients with endogenous Cushing’s syndrome (CS), medical therapy is often required to control severe hypercortisolism. Metyrapone and osilodrostat are both steroidogenic inhibitors targeting the 11β-hydroxylase, however, their...

Descripción completa

Detalles Bibliográficos
Autores principales: Detomas, Mario, Altieri, Barbara, Deutschbein, Timo, Fassnacht, Martin, Dischinger, Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9235400/
https://www.ncbi.nlm.nih.gov/pubmed/35769081
http://dx.doi.org/10.3389/fendo.2022.903545

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9235400/
https://www.ncbi.nlm.nih.gov/pubmed/35769081
http://dx.doi.org/10.3389/fendo.2022.903545

Ejemplares similares